Clinical Trial Update: A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) [Phase 3]

View source ↗

Summary

This update notes a Phase 3 safety and tolerability trial of VRDN-003 in Thyroid Eye Disease. The study is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• VRDN-003

Snippet

Sponsor: Viridian Therapeutics, Inc. | Conditions: Thyroid Eye Disease (TED) | Phase 3 | Status: ACTIVE_NOT_RECRUITING